Published in final edited form as:

Org Lett. 2014 February 7; 16(3): 820–823. doi:10.1021/ol403566w.

Asymmetric Alcohol C-H Allylation and *syn*-Crotylation: C9-C20 of Tetrafibricin

Takahiko Itoh, T. Patrick Montgomery, Antonio Recio III, and Michael J. Krische

University of Texas at Austin, Department of Chemistry and Biochemistry, Austin, TX 78712

Michael J. Krische: mkrische@mail.utexas.edu

Abstract

REDOX economy: merged ROH oxidation-C-C bond construction events.

The C9-C20 segment of the fibrinogen receptor inhibitor tetrafibricin was prepared in 10 steps (longest linear sequence). Ruthenium catalyzed enantioselective *syn*-crotylation is used to construct C9-C13. Iridium catalyzed asymmetric alcohol C-H allylation of a commercial malic acid derived alcohol is used to construct C14-C20. Recovery and recycling of the iridium catalyst is described.

Tetrafibricin¹ is a potent fibrinogen receptor inhibitor isolated from *Streptomyces neyagawaensis* NR0577 that functions by blocking GPIIb/IIIa receptors on the platelet surface, thus inhibiting platelet aggregation.^{2,3} While biosynthetically related to the oxo-polyene macrolide antibiotic lienomycin,⁴ tetrafibricin is acyclic and inactive against *Bacillus subtilis* and *Escherichia coli*. Further, the structure of tetrafibricin, which includes alternating 1,3-diol and 1,5-ene-diol motifs, represents a significant departure from all known fibrinogen receptor antagonists. Tetrafibricin has garnered interest with regard to the study of fibrinogen binding, platelet aggregation and as treatment of arterial thrombosis,⁵ which in turn has evoked interest in its preparation *via* total synthesis. Despite efforts reported from the laboratories of Cossy,⁶ Curran,⁷ Friestad,⁸ Roush⁹ and the present author,¹⁰ including the syntheses of a protected derivative of the natural product by Curran^{7d} and of *N*-acetyl dihydrotetrafibricin methyl ester by Roush,^{9c} the total synthesis of tetrafibricin remains an unmet challenge.

Using catalytic C-C bond-forming processes that occur through the addition, transfer or removal of hydrogen,¹¹ total syntheses of 6-deoxyerythronolide B,^{12a} bryostatin 7,^{12b} trienomycins A and F,^{12c} cyanolide A^{12d} and roxaticin^{12e} were completed in our laboratory. Due to the redox economy¹³ of the methods underlying their construction, these syntheses represent the most concise routes to any member of these respective natural product

Correspondence to: Michael J. Krische, mkrische@mail.utexas.edu.

Supporting Information Available. Spectral data for all new compounds (¹H NMR, ¹³C NMR, IR, HRMS). This material is available free of charge *via* the internet at <http://pubs.acs.org>.

families. Inspired by the unanswered synthetic challenges posed by tetrafibricin, a 12 step route to the C21-C40 segment was devised using iridium catalyzed alcohol C-H allylation developed in our laboratory.^{10,14} Here, we report a 10 step synthesis of the C9-C20 substructure of tetrafibricin featuring enantioselective methods for ruthenium catalyzed alcohol C-H *syn*-crotylation¹⁵ and iridium catalyzed alcohol C-H allylation.¹⁴

The C9-C20 substructure of tetrafibricin was envisioned to arise through the reductive coupling of bromide **6** to epoxide **13**. Synthesis of bromide **6** was readily accomplished through ruthenium catalyzed hydrohydroxyalkylation of 2-silyl-butadiene **2** with the *mono*-protected 1,3-propane diol **1**. A modification of our previously reported conditions,^{15a} which involves use of the catalyst generated from RuHCl(CO)(PPh₃)₃ and (*R*)-DM-SEGPHOS in the presence of substoichiometric sodium sulfate, provided the desired product of diene hydrohydroxyalkylation **3** in 75% yield with excellent control of *syn*-diastereo- and enantioselectivity (92% ee, 18:1 dr). Adduct **3** was converted to the *p*-methoxy benzylidene acetal in 87% yield upon DDQ oxidation.¹⁶ Finally, exposure of the alkenyl silane to pyridinium bromide perbromide gave the crude dibromide **5**, which was treated with sodium methoxide to furnish the alkenyl bromide **6** (Scheme 2).¹⁷

Synthesis of the C14-C20 epoxide **13** began with the asymmetric iridium catalyzed alcohol C-H allylation¹⁴ of the commercially available chiral alcohol **7** derived from (*S*)-malic acid. Using the cyclometallated iridium catalyst “(*S*)-**I**” generated *in situ* from [Ir(cod)Cl]₂, 4-chloro-3-nitrobenzoic acid, allyl acetate and (*S*)-BINAP, the desired homoallylic alcohol **8** was obtained in 69% isolated yield as a single diastereomer as determined by ¹H NMR of the crude reaction product. As previously noted,¹⁸ cyclometallated iridium catalysts of this type are remarkably stable to conventional silica gel flash chromatography. Given evidence that the carbonyl addition is turnover limiting,^{14b} the chromatographically stable π -allyl complex “(*S*)-**I**” is a potential catalyst resting state. In accord with this interpretation, “(*S*)-**I**” can be recovered from the reaction mixture and recycled to provide homoallylic alcohol **8** in 53% yield with equally high levels of diastereoselectivity. No further erosion in yield or selectivity was observed upon further iterations of recovery and recycling. Catalyst recovery and recycling, along with the ability to bypass discrete alcohol-to-aldehyde redox reactions, renders our asymmetric allylation protocol more cost effective (Scheme 3).

To complete the synthesis of epoxide **13**, homoallylic alcohol **8** was converted to the *tert*-butyl carbonate **9**, which was subjected to conditions for acid catalyzed methanolysis to furnish diol **10**. Primary benzyl protection of diol **10** using Taylor’s diphenylborinic acid catalyst¹⁹ was achieved with excellent levels of site-selectivity to provide *mono*-benzyl ether *mono*-Boc carbonate **11**. Modified Bartlett halocyclization of the Boc-carbonate²⁰ followed by treatment of the crude mixture with K₂CO₃ in methanol delivered the epoxy diol **12** in 48% yield as an 8:1 mixture of diastereomers. Protection of the diol as the acetonide provides the requisite epoxide **13** (Scheme 4).

To form the C9-C20 substructure of tetrafibricin, the cuprate derived from alkenyl bromide **6** was reacted with epoxide **13**.^{21,22} Initially, it was desired to use the commercially available lithium 2-thienyl(cyano)cuprate solution to form the higher order mixed organocuprate reagent,^{21b,22b} so as to limit the stoichiometry of alkenyl bromide **6** used in the transformation. However, this method failed to deliver serviceable quantities of adduct **14**. In contrast, using cuprous iodide as the copper source with two equivalents of alkenyl bromide, the product of epoxide opening was obtained in good yield, based on **13**.^{21a,22a} Silyl protection of alcohol **14**, followed by ozonolysis of olefin **15** delivered the C9-C20 fragment of tetrafibricin in 10 linear steps from the commercial malic acid derivative **7** and 15 total steps (Scheme 5).

In summary, we report a synthetic route to the C9-C20 substructure of tetrafibricin using ruthenium catalyzed enantioselective *syn*-crotylation to construct C9-C13 and iridium catalyzed asymmetric alcohol C-H allylation to construct C14-C20. This synthetic exercise led to the observation that the cyclometallated iridium complex used in the C-H allylation of primary alcohols may be recovered and recycled. The ability to perform multiple rounds of catalyst recovery and recycling, along with the ability to engage alcohols directly in catalytic C-C coupling in the absence of discrete alcohol-to-aldehyde redox reactions, makes the present iridium catalyzed allylation protocol both cost-effective and step-economical. A more systematic study of catalyst recovery and recycling, including immobilization of the catalyst on a solid support, will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Acknowledgment is made to the Robert A. Welch Foundation (F-0038), the NIH-NIGMS (RO1-GM093905) and the Center for Green Chemistry and Catalysis for partial support of this research. Dr. Taichiro Touge and Dr. Hideo Shimizu of Takasago are thanked for the generous donation of SEGPHOS ligands.

References

1. Isolation and structure assignment: Kamiyama T, Umino T, Fujisaki N, Satoh T, Yamashita Y, Ohshima S, Watanabe J, Yokose K. *J Antibiot.* 1993; 46:1039. [PubMed: 8360097] Kamiyama T, Itezono Y, Umino T, Satoh T, Nakayama N, Yokose K. *J Antibiot.* 1993; 46:1047. [PubMed: 8360098] Kobayashi Y, Czechitzky W, Kishi Y. *Org Lett.* 2003; 5:93. [PubMed: 12509899]
2. Satoh T, Yamashita Y, Kamiyama T, Watanabe J, Steiner B, Hadvary B, Arisawa M. *Thromb Res.* 1993; 72:389. [PubMed: 8303682]
3. Satoh T, Yamashita Y, Kamiyama T, Arisawa M. *Thromb Res.* 1993; 72:401. [PubMed: 8303683]
4. Pawlak J, Nakanishi K, Iwashita T, Borowski E. *J Org Chem.* 1987; 52:2896.
5. (a) Satoh T, Yamashita Y, Kamiyama T, Arisawa M. *Thromb Res.* 1993; 72:401. [PubMed: 8303683] (b) Satoh T, Yamashita Y, Kamiyama T, Arisawa M. *Thromb Res.* 1993; 72:401. [PubMed: 8303683] (c) Satoh T, Kouns WC, Yamashita Y, Kamiyama T, Steiner B. *Biochem J.* 1994; 301:785. [PubMed: 7519850] (d) Satoh T, Kouns WC, Yamashita Y, Kamiyama T, Steiner B. *Biochem Biophys Res Commun.* 1994; 204:325. [PubMed: 7524499]
6. BouzBouz S, Cossy J. *Org Lett.* 2004; 6:3469. [PubMed: 15387525]
7. (a) Gudipati V, BajPai R, Curran DP. *Collect Czech Chem Commun.* 2009; 74:774. (b) Zhang K, Gudipati V, Curran DP. *Synlett.* 2010:667. [PubMed: 20686632] (c) Gudipati V, Curran DP. *Tetrahedron Lett.* 2011; 52:2254. [PubMed: 21603053] (d) doctoral thesis. <http://d-scholarship.pitt.edu/6572/>
8. Friestad GK, Sreenilayam G. *Org Lett.* 2010; 12:5016. [PubMed: 20939544]
9. (a) Lira R, Roush WR. *Org Lett.* 2007; 9:533. [PubMed: 17249805] (b) Kister J, Nuhant P, Lira R, Sorg A, Roush WR. *Org Lett.* 2011; 13:1868. [PubMed: 21375316] (c) Nuhant P, Roush W. *J Am Chem Soc.* 2013; 135:5340. [PubMed: 23530855]
10. Kumpulainen ETT, Kang B, Krische MJ. *Org Lett.* 2011; 13:2484. [PubMed: 21469726]
11. For recent reviews on C-C bond forming hydrogenation and transfer hydrogenation, see: Bower JF, Krische MJ. *Top Organomet Chem.* 2011; 43:107. [PubMed: 21822399] Hassan A, Krische MJ. *Org Proc Res Devel.* 2011; 15:1236. Moran J, Krische MJ. *Pure Appl Chem.* 2012; 84:1729. [PubMed: 23430602]
12. (a) Gao X, Woo SK, Krische MJ. *J Am Chem Soc.* 2013; 135:4223. [PubMed: 23464668] (b) Lu Y, Woo SK, Krische MJ. *J Am Chem Soc.* 2011; 133:13876. [PubMed: 21780806] (c) Del Valle DJ, Krische MJ. *J Am Chem Soc.* 2013; 135:10986. [PubMed: 23862627] (d) Waldeck AR,

- Krische MJ. *Angew Chem Int Ed.* 2013; 52:4470.(e) Han SB, Hassan A, Kim IS, Krische MJ. *J Am Chem Soc.* 2010; 132:15559. [PubMed: 20961111]
13. For an overview of “redox economy” in organic synthesis, see: Baran PS, Hoffmann RW, Burns NZ. *Angew Chem Int Ed.* 2009; 48:2854.
14. For enantioselective iridium catalyzed alcohol C-H allylations employing allyl acetate, see: Kim IS, Ngai MY, Krische MJ. *J Am Chem Soc.* 2008; 130:6340. [PubMed: 18444616] Kim IS, Ngai MY, Krische MJ. *J Am Chem Soc.* 2008; 130:14891. [PubMed: 18841896] Lu Y, Kim IS, Hassan A, Del Valle DJ, Krische MJ. *Angew Chem Int Ed.* 2009; 48:5018. Hassan A, Lu Y, Krische MJ. *Org Lett.* 2009; 11:3112. [PubMed: 19586067] Schmitt DC, Dechert-Schmitt AMR, Krische MJ. *Org Lett.* 2012; 14:6302. [PubMed: 23231774] Dechert-Schmitt AMR, Schmitt DC, Krische MJ. *Angew Chem Int Ed.* 2013; 52:3195.
15. For enantioselective ruthenium catalyzed alcohol C-H crotylation via diene hydrohydroxyalkylation, see: Zbieg JR, Moran J, Krische MJ. *J Am Chem Soc.* 2011; 133:10582. [PubMed: 21627316] Zbieg JR, Yamaguchi E, McInturff EL, Krische MJ. *Science.* 2012; 336:324. [PubMed: 22442385] McInturff EL, Yamaguchi E, Krische MJ. *J Am Chem Soc.* 2012; 134:20628. [PubMed: 23234459]
16. Oikawa Y, Nishi T, Yonemitsu O. *Tetrahedron Lett.* 1983; 24:4037.
17. (a) Miller RB, Reichenbach T. *Tetrahedron Lett.* 1974; 15:543.(b) Miller RB, McGarvey G. *J Org Chem.* 1978; 43:4424.(c) Miller RB, McGarvey G. *J Org Chem.* 1979; 44:4623.
18. Gao X, Townsend IA, Krische MJ. *J Org Chem.* 2011; 76:2350. [PubMed: 21375283]
19. Lee D, Williamson CL, Chan L, Taylor MS. *J Am Chem Soc.* 2012; 134:8260. [PubMed: 22533533]
20. Bartlett PA, Meadows JD, Brown EG, Morimoto A, Jernstedt KK. *J Org Chem.* 1982; 47:4013. For recent examples: Smith AB III, Lin Q, Nakayama K, Boldi AM, Brook CS, McBriar MD, Moser WH, Sobukawa M, Zhuang L. *Tetrahedron Lett.* 1997; 38:8675. Stivala CE, Gu Z, Smith LL, Zakarian A. *Org Lett.* 2012; 14:804. [PubMed: 22260643]
21. For seminal reports of epoxide ring openings employing alkenyl cuprate reagents and their thienyl modified analogues, respectively, see: Herr RW, Wieland DM, Johnson CR. *J Am Chem Soc.* 1970; 92:3813. Lipshutz BH, Koerner M, Parker DA. *Tetrahedron Lett.* 1987; 28:945.
22. For selected examples from the total synthesis literature of related epoxide ring openings employing alkenyl cuprate reagents and their thienyl modified analogues, respectively, see: Guo J, Duffy KJ, Stevens KL, Dalko PI, Roth RM, Hayward MM, Kishi Y. *Angew Chem Int Ed.* 1998; 37:187. Smith AB III, Friestad GK, Barbosa J, Bertounesque E, Hull KG, Iwashima M, Qiu Y, Salvatore BA, Spoors PG, Duan JJ-W. *J Am Chem Soc.* 1999; 121:10468.

Scheme 1. Retrosynthetic Analysis of the Fibrinogen Receptor Inhibitor Tetrafibricin.^a

Scheme 2.

Synthesis of Alkenyl Bromide **6** via Ruthenium Catalyzed Hydrohydroxyalkylation of Diene **2**.^a

^aYields are of material isolated by silica gel chromatography. (*R*)-DM-SEGPPOS: (*R*)-(+)-5,5-bis(diphenylphosphino)-4,4-bi-1,3-benzodioxole. See Supporting Information for further details.

first cycle **second cycle** **Scheme 3.**Catalyst Recovery and Recycling in the Asymmetric Alcohol C-H Allylation of **7**.^a^aYields are of material isolated by silica gel chromatography. The third and higher cycles provided yields ranging between 50–60%. See Supporting Information for further details.

Scheme 4. Conversion of Homoallylic Alcohol **8** to Epoxide **13**.^a^aYields are of material isolated by silica gel chromatography. See Supporting Information for further details.

Scheme 5.

Reductive Coupling of Alkenyl Bromide **6** and Epoxide **13** to Form the C9-C20 Substructure of Tetrafibricin.^a

^aYields are of material isolated by silica gel chromatography. See Supporting Information for further details.